Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)

Clinical trial NCT05658510 · COMPLETED

Trial details

NCT number: NCT05658510
Sponsor: BioXcel Therapeutics Inc
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Agitation,Psychomotor Bipolar I Disorder Bipolar II Disorder Schizophrenia Schizoaffective Disorder Schizophreniform Disorders

Start date: 2022-11-21
Primary completion: 2025-08-15
Enrollment: 452

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.